Teacher Retirement System of Texas Sells 1,033 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Teacher Retirement System of Texas lowered its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 9.0% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 10,457 shares of the company’s stock after selling 1,033 shares during the period. Teacher Retirement System of Texas’ holdings in Kymera Therapeutics were worth $286,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of KYMR. Wellington Management Group LLP lifted its stake in Kymera Therapeutics by 14.9% during the 4th quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock valued at $213,514,000 after acquiring an additional 688,967 shares during the period. Avoro Capital Advisors LLC lifted its stake in Kymera Therapeutics by 14.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock valued at $207,184,000 after acquiring an additional 650,000 shares during the period. Deerfield Management Company L.P. Series C bought a new position in Kymera Therapeutics during the 4th quarter valued at about $23,856,000. Boxer Capital Management LLC bought a new position in Kymera Therapeutics during the 4th quarter valued at about $17,098,000. Finally, Janus Henderson Group PLC lifted its stake in Kymera Therapeutics by 2,397.9% during the 4th quarter. Janus Henderson Group PLC now owns 377,384 shares of the company’s stock valued at $15,197,000 after acquiring an additional 362,276 shares during the period.

Analysts Set New Price Targets

Several equities analysts have issued reports on KYMR shares. Jefferies Financial Group set a $64.00 target price on shares of Kymera Therapeutics and gave the company a “buy” rating in a research note on Wednesday, June 25th. Oppenheimer reiterated an “outperform” rating and issued a $53.00 price objective (down previously from $56.00) on shares of Kymera Therapeutics in a research note on Friday, June 27th. Guggenheim reiterated a “buy” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, June 3rd. Bank of America upgraded shares of Kymera Therapeutics from a “neutral” rating to a “buy” rating and set a $51.00 price objective on the stock in a research note on Monday, June 2nd. Finally, JPMorgan Chase & Co. increased their price objective on shares of Kymera Therapeutics from $57.00 to $64.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 3rd. Two equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $59.11.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bros. Advisors Lp Baker purchased 655,500 shares of the firm’s stock in a transaction that occurred on Monday, June 30th. The shares were bought at an average price of $44.00 per share, with a total value of $28,842,000.00. Following the completion of the purchase, the director directly owned 6,117,295 shares in the company, valued at $269,160,980. This trade represents a 12.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 6,349 shares of the company’s stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $311,101.00. The disclosure for this sale can be found here. Insiders have sold 48,349 shares of company stock valued at $2,334,301 over the last quarter. 16.01% of the stock is currently owned by insiders.

Kymera Therapeutics Price Performance

Shares of KYMR opened at $46.18 on Friday. Kymera Therapeutics, Inc. has a 1 year low of $19.45 and a 1 year high of $53.27. The company has a 50 day simple moving average of $40.99 and a two-hundred day simple moving average of $36.24. The firm has a market cap of $3.01 billion, a P/E ratio of -14.90 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.10. The company had revenue of $22.10 million for the quarter, compared to analysts’ expectations of $11.38 million. Kymera Therapeutics had a negative net margin of 409.07% and a negative return on equity of 30.11%. Kymera Therapeutics’s quarterly revenue was up 114.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.69) earnings per share. On average, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.